Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 8/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471805 | 0.82 | LMNA (0.51) | LMNASLC29A1NT5ERAB9ACYP3A4 | |
| SCHEMBL21263936 | 0.77 | LMNA (0.48) | LMNANT5EPNPP2RY11 | |
| SCHEMBL21263864 | 0.77 | SLC29A1 (0.56) | LMNASLC29A1RAB9ACYP3A4PKM | |
| SCHEMBL25688724 | 0.76 | SLC29A1 (0.49) | LMNASLC29A1RAB9ACYP3A4PKM | |
| SCHEMBL25688725 | 0.74 | SLC29A1 (0.39) | LMNASLC29A1RAB9ACYP3A4PKM | |
| SCHEMBL21264012 | 0.74 | SLC29A1 (0.46) | LMNASLC29A1RAB9ACYP3A4PKM | |
| SCHEMBL21263975 | 0.72 | LMNA (0.51) | LMNANT5EPNPP2RY11 | |
| SCHEMBL24258630 | 0.71 | CYP1A2 (0.46) | LMNASLC29A1RAB9ACYP3A4PKM | |
| SCHEMBL24258662 | 0.71 | SLC29A1 (0.40) | LMNASLC29A1RAB9ACYP3A4PKM | |
| SCHEMBL24444132 | 0.71 | CYP1A2 (0.46) | LMNASLC29A1RAB9ACYP3A4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | LMNA 1855/4885SLC29A1 537/4885NT5E 102/4885 |
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | LMNA 1855/4885SLC29A1 537/4885NT5E 102/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | LMNA 1855/4885SLC29A1 537/4885NT5E 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.